期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

卵巢浆液性癌病理发病机制研究进展 被引量：10

卵巢浆液性癌病理发病机制研究进展
原文传递
导出
摘要 卵巢癌是女性生殖系统常见的恶性肿瘤之一。目前，全世界每年约有20万以上的妇女罹患卵巢癌。在过去40年中，卵巢癌的治愈率没有明显提高，主要因卵巢癌早期没有特异的临床症状，并缺乏可靠的生物学标记物，一般在确诊时已是中晚期。因其对化疗产生耐药性，预后较差。基于病理学和分子遗传学研究的深入，
作者 汪向明 张帆 顾倩 马少平
机构地区 皖南医学院弋矶山医院病理科 皖南医学院病理教研室 皖南医学院弋矶山医院妇产科
出处 《中国实用妇科与产科杂志》 CAS CSCD 北大核心 2013年第3期236-240,共5页 Chinese Journal of Practical Gynecology and Obstetrics
关键词 卵巢浆液性癌 病理学 发病机制 分子遗传学 临床病理 ovary serous carcinomas pathology pathogenesis molecular genetics clinicopathological
分类号 R711.75 [医药卫生—妇产科学]
  • 相关文献

参考文献27

  • 1Kurman R J, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer:a proposed unifying theory[ J ]. Am Surg Pathol, 2010,34(3) :433-443.
  • 2Malpica A, Deavers MT, Karen Lu, et al. Grading ovarian serous carcinoma using a two-tierSystem [ J ]. Am J Surg Pathol, 2004, 28(4) :496-504.
  • 3Bodurka DC, Deavers MT,Tian Chunqiao, et al. Reclas sification of Serous Ovarian Carcinoma by a 2-Tier System [ J ]. Cancer, 2011,1:1-9.
  • 4Seidman JD, Horkayne-Szakaly I, Cosin JA, et al. Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum [ J ]. Gynecol Oncol, 2006,103 ( 2 ) : 703- 708.
  • 5WestfaU D, Roma AA, Silva EG. High-gTade serous carcinoma of the ovary[ J]. Ann Diagn Patho1,2009 ,13 :285-290.
  • 6林洁,杜娟,张春妤,谢巧婷,张波,刘从容.卵巢浆液性癌两级组织学分级系统的评估及p53蛋白过表达的意义[J].中华病理学杂志,2010,39(10):655-660. 被引量：21
  • 7Jie Li, Nisreen A, Shujie P, et al. Tubal origin of "ovarian" low- grade serous carcinoma [ J ]. Modem Pathology, 2011,24,1488- 1499.
  • 8Crum CP, Drapkin R, Miron A, et al. The distal fallopian tube : a new model for pelvic serous carcinogenesis[ J]. Curr Opin Obstet Gynecol,2007,19 ( 1 ) :3-9.
  • 9Cram CP, Mckeon DF, Xian WA. The oviduct and ovarian canc- er: causality, clinical implications, and " targeted prevention" [ J]. Clini Obstet Gyneco1,2012,55 ( 1 ) :24-35.
  • 10Gilbert L, Basso O. Screening of symptomatic women for ovarian cancer[ J ]. Lancet Onco1,2012,13 (4) : e139 -el40.

二级参考文献52

  • 1李守柔.辅助性免疫治疗提高妇科恶性肿瘤常规综合治疗效果的展望[J].中国实用妇科与产科杂志,2006,22(5):321-322. 被引量：1
  • 2杨蓉,冯捷,房祥忠,白符,成夜霞,刘晨,朱炜,李林.卵巢浆液性腺癌预后评分模型的建立及应用[J].中华妇产科杂志,2006,41(7):459-463. 被引量：10
  • 3吴霞,狄文.化疗对肿瘤免疫治疗的增益作用[J].中国肿瘤生物治疗杂志,2007,14(1):90-93. 被引量：5
  • 4Coleman S, Clayton A, Mason MD, et al. Recovery of CD8 + T-cell function during systemic chemotherapy in advanced ovarian cancer [J]. Cancer Res, 2005, 65(15) : 7000-7006.
  • 5Wu X, Feng QM, Wang Y, et al. The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy [J]. Cancer Immunol Immunother, 2009. 59(2) :279-291.
  • 6Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines [J]. Nat Med, 2004, 10 (9) : 909 -915.
  • 7Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape [J]. Nat Immunol, 2002, 3 ( 11 ) : 991-998.
  • 8Schlienger K, Chu CS, Woo EY, et al. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients [J]. Clin Cancer Res, 2003, 9(4) : 1517-1527.
  • 9Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer [ J ]. N Engl J Med, 2003, 348(3) : 203-213.
  • 10Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival [J]. Nat Med, 2004, 10(9) : 942- 949.

共引文献68

同被引文献75

  • 1杨群顶,孙培祥,李向丽,陈桂娥.卵巢囊腺癌的CT诊断[J].中国CT和MRI杂志,2005,3(4):43-45. 被引量：9
  • 2张晓丹,陈淑艳,潘芝梅,张明.卵巢囊腺癌的CT表现及分期[J].实用放射学杂志,2006,22(1):88-91. 被引量：9
  • 3徐海风.卵巢囊腺瘤与囊腺癌的CT诊断[J].临床放射学杂志,2006,25(5):446-448. 被引量：27
  • 4王琦,龚海洋,高京宏.肥胖人痰湿体质外周血基因表达谱特征研究[J].中医杂志,2006,47(11):851-853. 被引量：46
  • 5冯梅,陈桂林,李秀华,陈琴,郭慈仁.复发性卵巢上皮癌67例临床分析[J].福建医药杂志,2006,28(6):31-32. 被引量：3
  • 6Otis - Green S, Wakabayashi MT, Morgan R, et al. Palliative Care Op- portunities for Women with Advanced Ovarian Cancer Associated with In- traperitoneal Chemotherapy[J] .Journal of palliative medicine, 2013, 16(1):44-53.
  • 7Bamias A, Bamia C, Zagouri F, et al. Improved survival trends in plat- inum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first -line paclitaxel/platinum chemotherapy:the im- pact of novel agents[J]. Oncology,2012,84(3) : 158 - 165.
  • 8Chambers SK,Chow HS,Janicek MF,et al. Phase I trim of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian can- cer[J]. Clinical Cancer Research,2012,18(9) :2 668 -2 678.
  • 9Hoskins P, Vergote I, Cervantes A, et al. Advanced ovarian cancer: phase Ⅲ randomized study of sequential cisplatin topotecan and carboplatin pa- clitaxel vs carboplatin paclitaxel [ J]. Journal of the National Cancer Insti- tute,2010,102(20) : 1 547 - 1 556.
  • 10Moon JH, Lee HJ, Kang WD, et al. Prognostic value of serum CA - 125 in patients with advanced epithelial ovarian cancer followed by complete re- mission after adjuvant chemotherapy[J]. Obstetrics & gynecology sci- ence,2013,56(1) :29 -35.

引证文献10

二级引证文献36

中国实用妇科与产科杂志
2013年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部